Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
May 7, 2026
Ten Years of Kymera: Daring to Deliver on a New Class of Medicines
Nello Mainolfi, PhD, Founder, President and CEO
April 15, 2026
A Conversation with Kymera’s Chief Business Officer, Noah Goodman
Noah Goodman, MBA, Chief Business Officer
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
Showing 51 news results
December 6, 2021
Timmerman Report: Targeted Small Molecule Protein Degraders, Nello Mainolfi on the Long Run
Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of reach for small molecules. Nello Mainolfi, PhD, Founder, President & CEO shares more about Kymera’s work and mission.
Featured Presentations & Publications
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025